Cochrane · systematic review · CD001470
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
Mahapatra, J, Quraishi, SN, David, A, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
12
No studies
16
Included studies
NR
No studies 16 · 57.1%Ungraded 0 · 0%Very low 4 · 14.3%Low 8 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
FLUPENTHIXOL DECANOATE compared with ORAL ANTIPSYCHOTICS for schizophrenia or other similar psychotic disorders
Population: patients with schizophrenia or other similar psychotic disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response: mental state ‐ relapse ‐ medium term ‐ not reported FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Clinical response: mental state ‐ general score ‐ medium term ‐ not reported FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Clinical response: global state ‐ no clinical improvement ‐ medium term ‐ not reported FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Service utilisation: hospital admission ‐ medium/long term ‐ not reported FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Leaving the study early ‐ short term Rate of attrition FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | RR 3 [0.33, 27.23] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | RR 1.19 [0.77, 1.83] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Economic outcomes ‐ long term ‐ not reported FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE compared with OTHER DEPOT ANTIPSYCHOTICS for schizophrenia or other similar psychotic disorders
Population: patients with schizophrenia or other similar psychotic disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | RR 1.3 [0.87, 1.93] | 5 studies · 221 participants | Low Downgraded: risk of bias, imprecision |
Clinical response: mental state ‐ general score ‐ skew Brief Psychiatric Rating Scale (BPRS) FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | no estimate extracted | 0 studies · 1 participants | Very low Downgraded: risk of bias, imprecision |
Clinical response: global state ‐ no clinical improvement ‐ short term Rates of improvement FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | RR 0.67 [0.36, 1.23] | 1 study · 36 participants | Low Downgraded: risk of bias, imprecision |
Service utilisation: hospital admission ‐ medium/long term ‐ not reported FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Leaving the study early ‐ short/medium term Rate of attrition FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | RR 1.23 [0.76, 1.99] | 4 studies · 161 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term Numbers requiring anticholinergic medication FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | RR 1.38 [0.75, 2.52] | 3 studies · 102 participants | Low Downgraded: risk of bias, imprecision |
Economic outcomes ‐ long term ‐ not reported FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE HIGH DOSE compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) for schizophrenia or other similar psychotic disorders
Population: patients with schizophrenia or other similar psychotic disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | RR 1 [0.27, 3.69] | 1 study · 18 participants | Low Downgraded: imprecision, inconsistency |
Clinical response: mental state ‐ general score ‐ medium term Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126. FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | no estimate extracted | 1 study · 18 participants | Low Downgraded: risk of bias |
Clinical response: global state ‐ no clinical improvement ‐ short/medium term ‐ not reported FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | no estimate extracted | NR | No studies |
Service utilisation: hospital admission ‐ medium/long term ‐ not reported FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | no estimate extracted | NR | No studies |
Leaving the study early ‐ short/medium term Rate of attrition FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | RR 0.16 [0.03, 0.82] | 2 studies · 42 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term numbers requiring anticholinergic medication FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | no estimate extracted | 2 studies · 47 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Economic outcomes ‐ long term ‐ not reported FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE compared with FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) for schizophrenia or other similar psychotic disorders
Population: patients with schizophrenia or other similar psychotic disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | RR 0.34 [0.1, 1.15] | 1 study · 59 participants | Low Downgraded: risk of bias, imprecision |
Clinical response: mental state ‐ general score (BPRS) ‐ skew ‐ not reported FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | no estimate extracted | NR | No studies |
Clinical response: global state ‐ no clinical improvement ‐ short/medium term ‐ not reported FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | no estimate extracted | NR | No studies |
Service utilisation: hospital admission ‐ medium/long term ‐ not reported FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | no estimate extracted | NR | No studies |
Leaving the study early ‐ medium/long term ‐ not reported FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | no estimate extracted | NR | No studies |
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term ‐ not reported FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | no estimate extracted | NR | No studies |
Economic outcomes ‐ long term ‐ not reported FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) | no estimate extracted | NR | No studies |